Published in J Clin Oncol on September 01, 2008
Smoking, alcohol use, obesity, and overall survival from non-Hodgkin lymphoma: a population-based study. Cancer (2010) 1.12
Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up. Support Care Cancer (2015) 1.00
Obesity, insulin resistance, and cancer prognosis: implications for practice for providing care among cancer survivors. J Am Diet Assoc (2009) 0.87
Obesity and non-Hodgkin lymphoma survival in an ethnically diverse population: the Multiethnic Cohort study. Cancer Causes Control (2014) 0.84
Excess body weight and colorectal cancer survival: the multiethnic cohort. Cancer Causes Control (2015) 0.80
Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells. Oncol Lett (2013) 0.79
Recognition of comorbid diabetes and obesity in hospital records of newly diagnosed cancer patients. Ann Oncol (2009) 0.78
Visceral and subcutaneous fat as new independent predictive factors of survival in locally advanced gastric carcinoma patients treated with neo-adjuvant chemotherapy. J Cancer Res Clin Oncol (2014) 0.77
Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model. Cancer Biol Ther (2013) 0.77
Weight control interventions improve therapeutic efficacy of dacarbazine in melanoma by reversing obesity-induced drug resistance. Cancer Metab (2016) 0.75
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 3.74
Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol (2008) 2.74
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol (2008) 2.40
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell (2010) 3.70
Use of radioactive iodine for thyroid cancer. JAMA (2011) 2.98
Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer (2006) 2.79
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 2.77
Surgeon recommendations and receipt of mastectomy for treatment of breast cancer. JAMA (2009) 2.64
Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res (2005) 2.55
Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol (2004) 2.42
Decision involvement and receipt of mastectomy among racially and ethnically diverse breast cancer patients. J Natl Cancer Inst (2009) 2.18
Latina patient perspectives about informed treatment decision making for breast cancer. Patient Educ Couns (2008) 2.17
The role of sentinel lymph node biopsy for melanoma: evidence assessment. J Am Acad Dermatol (2005) 2.12
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Patient-centered care and breast cancer survivors' satisfaction with information. Patient Educ Couns (2005) 1.88
Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol (2006) 1.75
Comparative effectiveness of ductal carcinoma in situ management and the roles of margins and surgeons. J Natl Cancer Inst (2011) 1.69
The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer (2007) 1.64
Racial/ethnic differences in adequacy of information and support for women with breast cancer. Cancer (2008) 1.64
RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat (2005) 1.49
Racial/ethnic differences in quality of life after diagnosis of breast cancer. J Cancer Surviv (2009) 1.47
Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res (2005) 1.41
Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg (2005) 1.39
Dermatofibrosarcoma protuberans: how wide should we resect? Ann Surg Oncol (2010) 1.35
Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res (2008) 1.31
Study protocol: a randomized controlled trial of patient navigation-activation to reduce cancer health disparities. BMC Cancer (2010) 1.26
Patient perspectives on breast cancer treatment plan and summary documents in community oncology care: a pilot program. Cancer (2012) 1.25
Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat (2005) 1.24
EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development. Mod Pathol (2011) 1.21
Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer. Breast Cancer Res Treat (2013) 1.21
Structures and processes of care in ambulatory oncology settings and nurse-reported exposure to chemotherapy. BMJ Qual Saf (2011) 1.21
Sentinel lymph node biopsy performed after neoadjuvant chemotherapy is accurate in patients with documented node-positive breast cancer at presentation. Ann Surg Oncol (2007) 1.21
The impact of sociodemographic, treatment, and work support on missed work after breast cancer diagnosis. Breast Cancer Res Treat (2009) 1.19
A putative role for psoriasin in breast tumor progression. Cancer Res (2005) 1.19
EZH2 expands breast stem cells through activation of NOTCH1 signaling. Proc Natl Acad Sci U S A (2014) 1.18
Coordinating cancer care: patient and practice management processes among surgeons who treat breast cancer. Med Care (2010) 1.18
The role of clinicians in determining radioactive iodine use for low-risk thyroid cancer. Cancer (2012) 1.17
Does it matter where you go for breast surgery?: attending surgeon's influence on variation in receipt of mastectomy for breast cancer. Med Care (2010) 1.16
Variation in the management of thyroid cancer. J Clin Endocrinol Metab (2013) 1.15
Determinants of breast conservation rates: reasons for mastectomy at a comprehensive cancer center. Breast J (2009) 1.14
Patterns and correlates of adjuvant radiotherapy receipt after lumpectomy and after mastectomy for breast cancer. J Clin Oncol (2010) 1.12
Is blue dye indicated for sentinel lymph node biopsy in breast cancer patients with a positive lymphoscintigram? Ann Surg Oncol (2005) 1.11
Individualized strategy for dosing luteinizing hormone-releasing hormone agonists for androgen-independent prostate cancer: identification of outcomes and costs. J Oncol Pract (2006) 1.11
The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol (2011) 1.11
ADAM15 disintegrin is associated with aggressive prostate and breast cancer disease. Neoplasia (2006) 1.10
Employment of nurse practitioners and physician assistants in breast cancer care. J Oncol Pract (2010) 1.08
Pilot study of duloxetine for treatment of aromatase inhibitor-associated musculoskeletal symptoms. Cancer (2011) 1.07
Correlates of worry about recurrence in a multiethnic population-based sample of women with breast cancer. Cancer (2011) 1.07
Racial/ethnic differences in job loss for women with breast cancer. J Cancer Surviv (2010) 1.06
Small (< 2.0-cm) breast cancers: mammographic and US findings at US-guided cryoablation--initial experience. Radiology (2004) 1.04
Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. Ann Surg Oncol (2009) 1.04
Sentinel lymph node biopsy for breast cancer: how many nodes are enough? J Surg Oncol (2007) 1.04
The relationship between extent of thyroid cancer surgery and use of radioactive iodine. Ann Surg (2013) 1.03
Hot flashes, fatigue, treatment exposures and work productivity in breast cancer survivors. J Cancer Surviv (2008) 1.02
American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract (2010) 1.00
Physicians criticizing physicians to patients. J Gen Intern Med (2013) 1.00
Wide excision without radiation for desmoplastic melanoma. Cancer (2005) 1.00
Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer (2003) 1.00
Disparities in breast cancer adjuvant chemotherapy: moving beyond yes or no. J Clin Oncol (2009) 0.99
Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice. Cancer (2008) 0.98
Is there a role for sentinel lymph node biopsy in the management of sarcoma? Surg Oncol (2003) 0.98
Serum autoantibody profiling using a natural glycoprotein microarray for the prognosis of early melanoma. J Proteome Res (2010) 0.97
Pilot study using gabapentin for tamoxifen-induced hot flashes in women with breast cancer. Breast Cancer Res Treat (2004) 0.97
Perceptions of care coordination in a population-based sample of diverse breast cancer patients. Patient Educ Couns (2010) 0.97
Impact of adjuvant chemotherapy on long-term employment of survivors of early-stage breast cancer. Cancer (2014) 0.95
Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma? Cancer (2009) 0.94
Marginal treatment benefit in anaplastic thyroid cancer. Cancer (2013) 0.93
Randomized controlled trial of patient navigation for newly diagnosed cancer patients: effects on quality of life. Cancer Epidemiol Biomarkers Prev (2012) 0.93
Exercise and side effects among 749 patients during and after treatment for cancer: a University of Rochester Cancer Center Community Clinical Oncology Program Study. Support Care Cancer (2006) 0.93
Postmastectomy radiotherapy for breast cancer: patterns, correlates, communication, and insights into the decision process. Cancer (2009) 0.91
Patient-centered communication and prognosis discussions with cancer patients. Patient Educ Couns (2009) 0.90
Casting light on 25-hydroxyvitamin D deficiency in ovarian cancer: a study from the NHANES. Gynecol Oncol (2010) 0.90
Providers of follow-up care in a population-based sample of breast cancer survivors. Breast Cancer Res Treat (2014) 0.90
Lymphangiogenesis-independent resolution of experimental edema. Am J Physiol Heart Circ Physiol (2010) 0.90
Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res (2006) 0.90
Significance of multiple lymphatic basin drainage in truncal melanoma patients undergoing sentinel lymph node biopsy. Ann Surg Oncol (2006) 0.90
Lymphatic mapping and sentinel lymph node biopsy for patients with local recurrence after breast-conservation therapy. Ann Surg Oncol (2006) 0.89
Self-reported cognitive impairment in patients with cancer. J Oncol Pract (2007) 0.89
Sentinel lymph node biopsy is accurate and prognostic in head and neck melanoma. Cancer (2011) 0.88
Is a level III dissection necessary for a positive sentinel lymph node in melanoma? J Surg Oncol (2011) 0.87
Simultaneous analysis of cyclophosphamide, doxorubicin and doxorubicinol by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.87
Stability of decisional role preference over the course of cancer therapy. Psychooncology (2006) 0.86
Obesity and angiolymphatic invasion in primary breast cancer. Ann Surg Oncol (2009) 0.86
Pediatric melanoma: analysis of an international registry. Cancer (2013) 0.86
Internet use and anxiety in people with melanoma and nonmelanoma skin cancer. Dermatol Surg (2011) 0.85
Development of a question prompt list as a communication intervention to reduce racial disparities in cancer treatment. J Cancer Educ (2013) 0.85
Life-Threatening Disparities: The Treatment of Black and White Cancer Patients. J Soc Issues (2012) 0.85
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancer. Clin Cancer Res (2007) 0.85
A phoenix rising: who considers herself a "survivor" after a diagnosis of breast cancer? J Cancer Surviv (2012) 0.85
Referral patterns for patients with high-risk thyroid cancer. Endocr Pract (2013) 0.85
Role of nonclinical factors in the receipt of high-quality systemic adjuvant breast cancer treatment. J Clin Oncol (2011) 0.84
Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence. Ann Surg Oncol (2008) 0.84
Comprehensive axillary evaluation in neoadjuvant chemotherapy patients with ultrasonography and sentinel lymph node biopsy. Ann Surg Oncol (2005) 0.84
Melanoma: adjuvant therapy and other treatment options. Curr Treat Options Oncol (2003) 0.84
A BALB/c murine lung alveolar carcinoma used to establish a surgical spontaneous metastasis model. Clin Exp Metastasis (2004) 0.83
Complexities of adjuvant endocrine therapy in young premenopausal women. Oncology (Williston Park) (2009) 0.83
A composite measure of personal financial burden among patients with stage III colorectal cancer. Med Care (2014) 0.82